The discontinuation comes after the investigational drug, volenrelaxin, failed a related heart failure study in an ...

A new study led by Western researchers found frequent treatment with intranasal oxytocin – a hormone in the brain associated ...

The FDA granted approval to Eli Lilly and Company’s mirikizumab-mrkz (Omvoh) for Crohn disease, expanding its treatment reach ...

The San Diego–based company’s molecules avoid the well-trod GLP-1 pathway in favor of an alternate route in the gut.

K-Bio leaders pursue U.S. factories and conferences during Lunar New Year K-Bio executives opt for international business ...

“In addition to decreasing the inflammation by decreasing lesional staphylococcus aureus, the mupirocin treatment also lowered skin monocyte levels, which are important in driving cutaneous lupus,” ...

Madrigal Pharmaceuticals Inc. (MDGL) is our top conservative biotech recommendation for 2025. The company is in the sweet spot and de-risked with the first FDA-approved drug for chronic liver ...

The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai and partner Biogen's ...

Tectonic Therapeutic, Inc.'s stock surged 120% on positive Phase 1b data for TX45 in treating PH-HFpEF, offering a potential ...

In its second R&D alliance this week, Eli Lilly has formed a partnership with ... Flagship Pioneering's latest biotech launch, Mirai Bio, aims to help genetic medicine developers find the best ...

MoneyShow presents top investment ideas for 2024 from leading advisors. Part 7 includes Village Super Market, MARA Holdings, ...

Eli Lilly is still celebrating the FDA approval ... including Eisai's antibody-based E-2814 and small-molecule drugs from Annovis Bio (buntanetap), BioVie (bezisterim), and TauRx (HMTM).